Key result
Intramuscular ketamine maintains oxygen saturation with 0 adverse CV or respiratory side effects in children.
Why the study?
The effects of low-dose intramuscular ketamine on oxygen saturation in paediatric patients with congenital heart disease were not well characterized.
Does intramuscular ketamine 3 mg kg-1 affect oxygen saturation in children with congenital heart disease?
Does intramuscular ketamine 3 mg kg-1 affect oxygen saturation in children with congenital heart disease?
Low-dose intramuscular ketamine is a safe pre-induction agent that maintains or improves oxygen saturation in children with congenital heart disease.
May support IM ketamine pre-induction in pediatric CHD; hypothesis-generating and requires randomized confirmation.
Forty‐seven children with congenital heart disease received ketamine 3 mg kg−1 intramuscularly as a pre‐induction agent. During the 10 min observation period following ketamine administration no adverse cardiovascular or respiratory side‐effects were seen. Arterial oxygen saturation as measured by pulse oximetry remained constant in all patients. In the group of children with cyanotic heart disease, there was a trend towards improvement of oxygen saturation which became significant 10 min after ketamine administration. We conclude that ketamine is a useful pre‐induction agent when used in the appropriate dose range.
No takes yet. Share an insight, caveat, or question.
Fleischer et al. (1991) studied Congenital heart disease (n=47). Ketamine was evaluated on Arterial oxygen saturation and adverse cardiovascular or respiratory side-effects. Intramuscular ketamine (3 mg/kg) maintained constant arterial oxygen saturation and caused 0 adverse cardiovascular or respiratory side-effects over 10 minutes in 47 children.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: